Form SCHEDULE 13D/A PRECIGEN, INC. Filed by: KIRK RANDAL J
Tweet
Share
E-mail|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 22)*
|
PRECIGEN, INC. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
(CUSIP Number) |
Third Security, LLC 1881 Grove Avenue, Attention: April D. Jones Radford, VA, 24141 5406337900 John Owen Gwathmey, Esq. Troutman Pepper Locke Building, 1001 Haxall Point Richmond, VA, 23219 8046971239 David I. Meyers, Esq. Troutman Pepper Locke Building, 1001 Haxall Point Richmond, VA, 23219 8046971239 Troutman Pepper Locke, LLP Troutman Pepper Locke Building, 1001 Haxall Point Richmond, VA, 23219 8046971239 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
03/30/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
RANDAL J. KIRK | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
133,956,416.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
35.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
The indicated amount of Common Stock beneficially owned by Mr. Kirk assumes the full conversion of (i) 988,659 Options to Purchase Common Stock, which are fully vested and exercisable at the discretion of Mr. Kirk, and (ii) 16,666,667 Warrants to Purchase Common Stock, which are fully vested and exercisable at the discretion of Mr. Kirk.
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
R.J. KIRK DECLARATION OF TRUST | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
97,339,485.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
26.1 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
OO - trust; The indicated amount of Common Stock beneficially owned by RJ DOT assumes the full conversion of 16,666,667 Warrants to Purchase Common Stock, which are fully vested and exercisable at the discretion of Mr. Kirk.
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
THIRD SECURITY, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
VIRGINIA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
21,843,458.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
OO - limited liability company
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock | |
| (b) | Name of Issuer:
PRECIGEN, INC. | |
| (c) | Address of Issuer's Principal Executive Offices:
20374 Seneca Meadows Parkway, Germantown, Germantown,
MARYLAND
, 20876. | |
Item 1 Comment:
This Amendment No. 22 (the "Amendment") amends and supplements the Statement on Schedule13D, dated March 27, 2014 and filed on April 7, 2014, as amended by Amendment No. 1 dated December 31, 2014 and filed on January 5, 2015, by Amendment No. 2 dated May 31, 2016 and filed June 2, 2016, by Amendment No. 3 dated July 24, 2017 and filed July 26, 2017, by Amendment No. 4 dated October 16, 2017 and filed October 23, 2017, by Amendment No. 5 dated December 29, 2017 and filed on January 2, 2018, by Amendment No. 6 dated January 19, 2018 and filed January 22, 2018, by Amendment No. 7 dated July 3, 2018 and filed July 6, 2018, by Amendment No. 8 dated May 13, 2019 and filed May 15, 2019, by Amendment No. 9 dated May 24, 2019 and filed on May 24, 2019, by Amendment No. 10 dated June 6, 2019 and filed on June 10, 2019, by Amendment No. 11 dated January 1, 2020 and filed on January 6, 2020, by Amendment No. 12 dated January 31, 2020 and filed on February 4, 2020, by Amendment No. 13 dated August 11, 2020 and filed on August 13, 2020, by Amendment No. 14 dated December 17, 2020 and filed on December 21, 2020, by Amendment No. 15 dated October 6, 2022 and filed on October 7, 2022, by Amendment No. 16 dated January 27, 2023 and filed on January 31, 2023, by Amendment No. 17 dated May 2, 2024 and filed on May 3, 2024, by Amendment No. 18 dated August 9, 2024 and filed on August 13, 2024, by Amendment No. 19 dated and filed on December 30, 2024, by Amendment No. 20 dated September 17, 2025 and filed on September 19, 2025 and by Amendment No. 21 dated November 19, 2025 and filed on November 21, 2025 (the "Original Schedule 13D"), relating to the Common Stock, no par value per share (the "Common Stock"), of Precigen, Inc., formerly known as Intrexon Corporation, a Virginia corporation (the "Company"). Mr. Randal J. Kirk ("Mr. Kirk"), the R.J. Kirk Declaration of Trust, a revocable trust established by Mr. Kirk ("RJ DOT"), and Third Security, LLC, a Virginia limited liability company that is controlled by Mr. Kirk ("Third Security" and, together with Mr. Kirk, the RJ DOT, and Third Security, the "Reporting Persons") are filing this Amendment to disclose the sale of an aggregate of 4,772,781 shares of Common Stock by certain entities under the common control of Mr. Kirk ( the "Selling Entities"), in open market transactions on March 30, 2026. | ||
| Item 2. | Identity and Background | |
| (a) | See Original Schedule 13D | |
| (b) | See Original Schedule 13D | |
| (c) | See Original Schedule 13D | |
| (d) | See Original Schedule 13D | |
| (e) | See Original Schedule 13D | |
| (f) | See Original Schedule 13D | |
| Item 4. | Purpose of Transaction | |
Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows:
The information set forth in Items 3 and 6 is incorporated herein by reference.
The Selling Entities sold a total of 4,772,781 shares of Common Stock in open market transactions on March 30, 2026, for aggregate net proceeds of approximately $15,581,221. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | The responses to Items 11 and 13 of the cover pages, as well as the applicable comments thereto, to this Amendment No. 22 are incorporated herein. The percentage ownership is calculated based on 353,928,672 shares of Common Stock issued and outstanding as of February 15, 2026, as disclosed in the Company's Annual Report on Form 10K for the period ended December 31, 2025 and filed on March 25, 2026 increased by (i) 149,997 shares of Common Stock issued on March 10, 2026 to certain directors of the Company as equity compensation as reported by the Company on Forms 4 filed on March 12, 2026, of which 28,490 shares were issued to Mr. Kirk, (ii) 646,551 shares of Common Stock issued on March 13, 2026 to certain Directors of the Company as a result of the vesting of Restricted Stock Units issued in 2025 as reported by the Company on Forms 4 filed on March 16, 2026, of which 143,678 were issued to Mr. Kirk, (iii) 488,441 shares of Common Stock issued on March 18, 2026 to certain officers of the Company in the form of immediately vested Restricted Stock Units as reported by the Company on Forms 4 filed on March 20, 2026, (iv) 16,666,667 shares of Common Stock issuable to Mr. Kirk upon exercise of Warrants to Purchase Common Stock, which are exercisable within sixty (60) days; and (v) 988,659 shares of Common Stock issuable to Mr. Kirk upon exercise of Options to Purchase Common Stock, which are exercisable within sixty (60) days. | |
| (b) | The responses to Items 7, 8, 9 and 10 of the cover pages to this Amendment No. 22 are incorporated herein. | |
| (c) | Except as disclosed herein, the annual equity compensation granted to Mr. Kirk, which was previously disclosed in a Form 4 dated March 10, 2026 and filed on March 12, 2026, and the vesting of Restricted Stock Units granted to Mr. Kirk, which was previously disclosed in a Form 4 dated March 13, 2026 and filed on March 16, 2026, none of the Reporting Persons have engaged in any transactions in the Company's Common Stock in the past 60 days. | |
| (d) | Not applicable | |
| (e) | Not applicable | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Item 6 of the Original Schedule 13D is hereby amended and supplemented to include the responses in Item 4 above. | ||
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit 1 Joint Filing Agreement, dated as of March 31, 2026, by and among Randal J. Kirk, R.J. Kirk Declaration of Trust, and Third Security, LLC. | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Precigen receives FDA orphan drug exclusivity for PAPZIMEOS through 2032
- Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
13DSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
